Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients

Pathology International

Volumn 62, Issue 3, 2012, Pages 167-175

  Lee, Sang Hyub ^a,b   Kim, Haeryoung ^a,b   Hwang, Jin Hyeok ^a,b   Lee, Hye Seung ^a,b   Cho, Jai Young ^a,b   Yoon, Yoo Seok ^a,b   Han, Ho Seong ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Breast cancer resistance protein; Immunohistochemistry; Multidrug resistance; Pancreatic cancer; Prognosis

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN ASSOCIATED PROTEIN 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, PANCREATIC DUCTAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; P-GLYCOPROTEIN; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862830288     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2011.02772.x     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Jung KW, Won YJ, Park S etal. Cancer statistics in Korea: Incidence, mortality and survival in 2005. J Korean Med Sci 2009; 24: 995-1003.
3. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: A review. Cancer 2008; 112: 243-9.
4. Griffin JF, Smalley SR, Jewell W etal. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66: 56-61.
5. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21: 195-200.
6. Abbruzzese JL. Adjuvant therapy for surgically resected pancreatic adenocarcinoma. JAMA 2008; 299: 1066-7.
7. Boeck S, Ankerst DP, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: Systematic review of randomized controlled trials and meta-analysis. Oncology 2007; 72: 314-21.
8. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
9. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-32.
10. Oettle H, Post S, Neuhaus P etal. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-77.
11. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71: 537-92.
12. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
13. Han B, Zhang JT. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 2004; 4: 31-42.
14. Lage H. ABC-transporters: Implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003; 22: 188-99.
15. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216-37.
16. Suwa H, Ohshio G, Arao S etal. Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: Relevance to indicator of better prognosis. Jpn J Cancer Res 1996; 87: 641-9.
17. Lu Z, Kleeff J, Shrikhande S etal. Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 2000; 21: 240-47.
18. Kool M, van der Linden M, de Haas M etal. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 1999; 96: 6914-9.
19. Schaarschmidt T, Merkord J, Adam U etal. Expression of multidrug resistance proteins in rat and human chronic pancreatitis. Pancreas 2004; 28: 45-52.
20. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84.
21. Marques DS, Sandrini JZ, Boyle RT, Marins LF, Trindade GS. Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leuk Res 2010; 34: 757-62.
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Andy Trotti I. AJCC Cancer Staging Manual, 7th edn. New York: Springer, 2010.
23. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340-58.
24. Diestra JE, Scheffer GL, Catala I etal. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002; 198: 213-9.
25. Konig J, Hartel M, Nies AT etal. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 2005; 115: 359-67.
26. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009; 568: 161-73.
27. Li C, Heidt DG, Dalerba P etal. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-37.
28. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007; 6: 92-7.
29. Wang YH, Li F, Luo B etal. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 2009; 56: 371-8.
30. Chen Z, Liu F, Ren Q etal. Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer 2010; 126: 841-51.
31. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
32. Hagmann W, Jesnowski R, Faissner R, Guo C, AT LJM. P-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology 2009; 9: 136-44.
33. Hagmann W, Jesnowski R, Lohr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010; 12: 740-47.
34. Oguri T, Achiwa H, Sato S etal. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: A role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 2006; 5: 1800-806.
35. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005; 4: 855-63.
36. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001; 276: 46400-407.
37. Scheffer GL, Kool M, de Haas M etal. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 2002; 82: 193-201.
38. O'Driscoll L, Walsh N, Larkin A etal. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res 2007; 27: 2115-20.